Ongoing, recruitingHuman Pharmacology (Phase I)- OtherInterventional

MK-8507 Extended Multiple Dose Study

At a glance

Status

Ongoing, recruiting

Phase

Human Pharmacology (Phase I)- Other

Sponsor

Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC

Enrolment target

80

Start

02 Oct 2023

HIV-1 infection

Who may be eligible?

Age 18 Years to any · Sex: All

Locations (1)

—
Belgium

How to find out more

Official trial record

Always speak to your GP or specialist before deciding to take part in a study.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.